As docetaxel is proven to be effective in late stages of prostate cancer with a large tumour burden it should be effective in primarily treated intermediate and high risk prostate cancer as an adjuvant treatment after radiotherapy to prevent early relapse. This will therefore be tested in a randomised phase III trial where patients will be randomized either to docetaxel or surveillance

Primary endpoint:

• PSA progression rate, ASTRO guidelines.

Secondary endpoints:

• PSA doubling time after progression
• Quality of Life (QoL)
• Safety
• Metastases free survival
• Overall survival

Inclusion Criteria:

• Men > 18 and ≤75 years of age.

• WHO/ECOG performance status 0 - 1.

• Histological proven adenocarcinoma of the prostate within 12 months prior to randomisation

• One of the following:

  • T2 with Gleason score 7(4+3 ) and PSA >10 ng/ml to < 70 ng/ml
  • T2 with Gleason 8-10, any PSA < 70 ng/ml
  • any T3 tumour

• Prior neoadjuvant hormone therapy is mandatory for all patients

• Adequate haematological-, liver- and kidney function. (Hemoglobin > 110 g/l, neutrophils > 1.5 x 109/ l, platelets > 150 x 109/ l, ASAT and ALAT < 1.5 x ULN, ALP < 1.5 x ULN, creatinine < 1.5 x ULN)

• Written informed consent

Exclusion Criteria:

• M+
• N+ clinical or pathological
• Patients with a history of previous malignant disease. Exceptions should be made for basal cell carcinoma (BCC) and squamous cell carcinoma of the skin. Exceptions should also be made for curatively treated malignant disease, which has been disease free for the past five years.
• Previous radiotherapy to the pelvic region.
• Previous chemotherapy within 5 years.
• Systemic corticosteroids within 6 months prior to randomisation.
• Unstable cardiovascular disease, including myocardial infarction, within 6 months prior to randomisation.
• Active untreated infectious disease, including tuberculosis, MRSA.
• Active gastric ulcer.
• Known hypersensitivity to Polysorbate 80 (an excipient of docetaxel)
• Other serious illness or medical condition